Pharma looks to big data, blockchain, cloud, security

IT-Online | November 05, 2019

Big data, blockchain, cloud computing and cybersecurity are the main technologies where pharma companies see the need to invest. This is according to GlobalData’s latest report, “Emerging Technology Trends Survey – Pharma 2019”, which reveals that over 70% of pharma executives, who have some level of responsibility with regards to the implementation of new and emerging technologies, prioritise data protection and storage solutions for their investments. Urte Jakimaviciute, senior director of market research at GlobalData, comments: “There is a sizable market on the dark web for healthcare industry related data and breaking into pharmaceutical companies’ systems can expose information related to clinical trials, trade secrets, and IP associated with drug formulation processes and technologies. “Any cyberattack that leaks confidential information can affect not only revenues but also damage brand reputation, disrupt the supply chain, or result in litigating actions.” The pharmaceutical industry is one of the most regulated industries in the world, with companies being required to comply with a number of regulations covering areas ranging from clinical trials to manufacturing and advertising.

Spotlight

How can I trust my data? This is a common concern for many researchers using particle measurement instrumentation. Is the data affected in any way by the measurement technology, or alternatively by the user during sample preparation or by the analysis parameters employed? To answer this question we need to consider the use of independent and orthogonal measurement techniques in order to provide confidence and measurement validation.

Spotlight

How can I trust my data? This is a common concern for many researchers using particle measurement instrumentation. Is the data affected in any way by the measurement technology, or alternatively by the user during sample preparation or by the analysis parameters employed? To answer this question we need to consider the use of independent and orthogonal measurement techniques in order to provide confidence and measurement validation.

Related News

PHARMA TECH

InnovaCare Signs Agreement with MedAvail to Open Three SpotRx Locations in Florida

InnovaCare | November 09, 2021

MedAvail Holdings, Inc. a technology-enabled retail pharmacy company, will be opening an initial three SpotRx locations with InnovaCare Health in Florida in the fourth quarter of 2021. In-clinic SpotRx kiosks and courier home delivery, supported by onsite SpotRx clinic account managers, will be available to patients at three Trinity Medical Center clinics in the Lakeland area. Trinity Medical Center is part of the InnovaCare Health clinical network. SpotRx Pharmacy is the retail pharmacy brand owned and operated by MedAvail in the United States, which deploys and operates the MedAvail MedCenters. “Our physician-led models and innovative technology have placed InnovaCare on the forefront of healthcare transformation for 20 years. We are excited to be continuing this tradition through our partnership with MedAvail and embedding the SpotRx pharmacy in our clinicsWe believe that this collaboration with our skilled clinical teams will result in improved health outcomes for our patients – it is a game-changing technology and the future for pharmacy services.” Connie Garcia, Pharm D., Pharmacy Manager of InnovaCare Health and Trinity Medical Center InnovaCare Health operates more than 30 clinics and is recognized as a leader in transforming care delivery. With the SpotRx embedded pharmacy model, InnovaCare Health patients will receive: Immediate access to prescriptions at the three Trinity Medical Center clinics Free contactless next-day home delivery for all prescriptions and over-the-counter medications Follow up care calls from a local SpotRx pharmacist after receiving the prescription Refill reminder calls on all chronic medications to schedule free delivery or in-clinic pick-up Instant access to SpotRx pharmacists via kiosk or phone “We are honored to support InnovaCare in its efforts to deliver compassionate, high-quality care tailored to each distinct patient population it serves,” said Ed Kilroy, Chief Executive Officer of MedAvail. “Our partnership is another key part of our continued expansion in Florida with our embedded pharmacy solution. We are committed to collaborating with InnovaCare over time to meet its patients’ medication access and adherence needs.” About InnovaCare InnovaCare Health improves the lives of members and physicians through innovative solutions for value-based healthcare. Through an integrated portfolio of health plans, medical service organizations, clinical networks and more, the company manages more than 500,000 lives, including more than 150,000 dual-eligible beneficiaries. InnovaCare’s Medicare Advantage plans have received NCQA accreditation and 4.5-star quality ratings from the Centers for Medicare and Medicaid Services (CMS). About SpotRx SpotRx places control of the pharmacy experience back in the hands of consumers. SpotRx is a telehealth platform that delivers remote pharmacist consultations through an on-site dispensing kiosk, supplemented with home delivery capability. About MedAvail MedAvail Holdings, Inc. (NASDAQ: MDVL) is a technology-enabled pharmacy organization, providing turnkey in-clinic pharmacy services through its proprietary robotic dispensing platform, the MedAvail MedCenter, and home delivery operations, to Medicare clinics. MedAvail helps patients to optimize drug adherence, resulting in better health outcomes.

Read More

PHARMACY MARKET

To Form a Worldwide CDMO for Inhalation Treatment Drugs, Formosa Laboratories, HCmed, and Formosa Pharmaceuticals Signed MoU

HCmed Innovations Co., Ltd | March 07, 2022

HCmed Innovations, Co., Ltd. (HCmed) has announced a strategic agreement with Formosa Laboratories, Inc. and Formosa Pharmaceuticals, Inc. to expand its inhalation therapy business by offering contract development and manufacturing services. The three parties expect to become a one-stop shop in the biopharmaceutical industry as a full-service contract development and manufacturing organization by combining HCmed's vibrating mesh nebulizers, Formosa Laboratories' drug development and manufacturing capabilities, and Formosa Pharmaceuticals' APNT nanotechnology platform (CDMO). According to data, the global market for inhalation drugs will reach $25 billion in 2020. Furthermore, as the COVID-19 pandemic has increased demand for respiratory treatment drugs over the last two years, so needs for developing respiratory drugs, prompting several well-known global pharmaceutical companies to take the lead in incorporating HCmed's proprietary mesh technology into the development of their inhaled products. "Currently, global CDMO companies that focus on developing drug-device combination products cannot only provide their Pharma partners with a platform to deliver drugs, but also with integrated services that extend to drug development, mass production, and product packaging. Through these services, the combination product development time can be shortened, and costs can be reduced. With this objective, HCmed, Formosa Laboratories, and Formosa Pharmaceuticals aim to provide a fully integrated CDMO service platform, which is expected to expand the companies' business further, providing fully-integrated solutions and creating long-term win-win relationships." CEO of HCmed, Jason Cheng The two companies have similar ideas on how to grow their CDMO businesses. In the respiratory medicine industry, the agreement represents the merging of three significant leaders in the biotechnology and high-end medical device industries. With Formosa Pharmaceuticals' nanotechnology platform, Formosa Laboratories' API, ADC, and injection development and production experience, and HCmed's technology in developing customized mesh nebulizers, the parties hope to provide a comprehensive service across the entire development process, including early drug development, clinical trial execution, mass production, and product launch. This partnership is

Read More

RESEARCH

Two Labs, an Envision Pharma Group Company Acquires Riparian

Two Labs | July 08, 2021

Two Labs, an industry-leading pharma services company and a subsidiary of Envision Pharma Group, announced today the acquisition of Riparian, a pharma consulting and SaaS company that assists manufacturers with pricing regulations, reporting, strategies, and program operations. The acquisition expands Two Labs' pharma service offerings, allowing the company to offer greater insights into the financials associated with drug launch and management, better positioning manufacturers for long-term success. In addition, Riparian's in-depth knowledge of government pricing regulations and program operations, combined with their consulting, business process outsourcing, and software capabilities, enables clients to understand the financials of their drug better, ensuring that the prices reported to the government are in accordance with the current government statutes and regulations. Riparian and Two Labs will collaborate to accelerate parent company Envision Pharma Group's plans for expansion in the growing biotech pharma sector in the United States. In November 2020, Envision acquired Two Labs. Riparian will continue to operate from its current headquarters in Henderson, Nevada, with offices in Pasadena, California, and Johnson City, Tennessee. In addition, David Chan and Cynthia Hwang, co-founders, will continue with the company. About Two Labs Two Labs is a leading pharmaceutical services company that offers pharmaceutical manufacturers a range of market access, market intelligence, and commercialization services. Two Labs has managed over 200 new product launches and over 290 in-market projects from pre-launch through loss of exclusivity since its start in 2003. About Envision Pharma Group Envision Pharma Group, founded in 2001, is a global, innovative technology and scientific communications company that serves pharmaceutical, biotechnology, and medical device companies. Envision is a leading provider of evidence-based communication services and industry-leading technology solutions (iEnvision) with applications in various areas of medical affairs and related functional responsibility. Envision Pharma Group serves over 90 companies, including all top 20 pharmaceutical companies, with services and technology solutions. About Riparian Riparian is a pharma Consulting, Outsourcing, and SaaS company based in Henderson, Nevada, assisting manufacturers in navigating government pricing regulations, reporting, strategies, and program operations. Riparian is a rapidly growing, innovative company supported by a team of industry experts.

Read More